Results 81 to 90 of about 465 (157)

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. [PDF]

Cancer Med
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, Yoneyama F, Hamaya T, Togashi K, Fujita N, Okamoto T, Ohyama C, Hatakeyama S.   +12 more
europepmc   +1 more source

Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients. [PDF]

PLoS One
Liu J, Liu X, Zeng H, Tong Y, Chen Z, Dong Z.   +5 more
europepmc   +1 more source

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide. [PDF]

J Comp Eff Res
Lowentritt BH, Burbage S, Khilfeh I, Pilon D, Du S, Rossi C, Kinkead F, Diaz L, Brown G.   +8 more
europepmc   +1 more source

Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide. [PDF]

Front Immunol
Wang Q, Ren ZT, Wu HF, Gu HC, Li XW, Tang ZL.   +5 more
europepmc   +1 more source

Pharmacist Intervention in Outpatients With Prostate Cancer Prevents Apalutamide-induced Skin Adverse Events. [PDF]

In Vivo
Umehara K, Saito Y, Takada S, Yamagishi K, Takada N, Maruyama S, Harabayashi T, Hashishita H.   +7 more
europepmc   +1 more source

Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. [PDF]

Jpn J Clin Oncol
Tohi Y, Kobayashi K, Daizumoto K, Sekino Y, Fukuhara H, Niigawa H, Katayama S, Shimizu R, Takamoto A, Nishimura K, Nagami T, Hayashida Y, Hirama H, Shiraishi K, Tomida R, Kobatake K, Inoue K, Miyaji Y, Bekku K, Morizane S, Miura N, Wada K, Sugimoto M, Chu-shikoku Japan Urological Consortium .   +23 more
europepmc   +1 more source

Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. [PDF]

Int J Clin Pharm
Pons-Fuster E, Gonzalez-Ponce CM, Ros-Martinez S, Fernández-Ávila JJ, Díaz-Carrasco MS, Espuny-Miró A.   +5 more
europepmc   +1 more source

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. [PDF]

Prostate Cancer Prostatic Dis
Shore N, Hafron J, Saltzstein D, Bhaumik A, Aggarwal P, Phillips J, McGowan T.   +6 more
europepmc   +1 more source

Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety. [PDF]

Medicine (Baltimore)
Zhang M, Wan L, Yao Y, Wu R, Li W, Gu P.
europepmc   +1 more source

Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. [PDF]

J Cancer Res Clin Oncol
Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, Ludwig M, Huwe P, Maywurm M, Bartsch-Polle A, Weber J, Thiemer M, Varughese D.   +12 more
europepmc   +1 more source